Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Theresa N. Operaña
Observed names:
TN Operana,
Theresa N Operaña,
Theresa N. Operana,
Theresa Operaña
Institutions:
Santa Barbara Cottage Hospital,
VA Central California Health Care System,
Comprehensive Cancer Centers of Nevada
Observed institutions:
Joslin Diabetes Center,
Harvard University,
Washington University in St. Louis,
Santa Barbara Cottage Hospital,
University of California San Diego,
VA Central California Health Care System,
Harvard Stem Cell Institute,
Comprehensive Cancer Centers of Nevada
show all 8
OpenAlex ID:
A5087264100
Lipid-mediated regulation of SKN-1/Nrf in response to germ cell absence
2015
·
Michael J Steinbaugh
, Sri Devi Narasimhan
, et al.
·
eLife
·
213
Oligomerization of the UDP-glucuronosyltransferase 1A Proteins
2006
·
Theresa N. Operaña
, Robert H. Tukey
·
Journal of Biological Chemistry
·
74
PDF
ERK Kinase Inhibition Stabilizes the Aryl Hydrocarbon Receptor
2004
·
Shujuan Chen
, Theresa Operaña
, et al.
·
Journal of Biological Chemistry
·
56
Human CYP1A1GFP Expression in Transgenic Mice Serves as a Biomarker for Environmental Toxicant Exposure
2006
·
Theresa N. Operaña
, Nghia Nguyen
, et al.
·
Toxicological Sciences
·
15
Molecular classification of cancer with the 92-gene assay in cytology and limited tissue samples
2016
·
Elena F. Brachtel
, Theresa N. Operaña
, et al.
·
Oncotarget
·
9
PDF
Multi-Institutional, Prospective Clinical Utility Study Evaluating the Impact of the 92-Gene Assay (CancerTYPE ID) on Final Diagnosis and Treatment Planning in Patients With Metastatic Cancer With an Unknown or Unclear Diagnosis
2018
·
Sachdev P. Thomas
, Lauren E. Jacobson
, et al.
·
JCO Precision Oncology
·
6
Molecular diagnosis with the 92-gene assay (92-GA) and decision-impact on treatment: Final results from a prospective, multi-disciplinary study.
2015
·
Sachdev P. Thomas
, Lauren Jacobson
, et al.
·
Journal of Clinical Oncology
·
2
Clinical utilization of Breast Cancer Index (BCI) for late recurrence risk assessment and prediction of extended endocrine therapy (EET) benefit in early stage HR+ breast cancer.
2017
·
Reshma L. Mahtani
, Vijayakrishna K. Gadi
, et al.
·
Journal of Clinical Oncology
·
1
Molecular diagnosis with the 92-Gene Assay (92-GA) and decision-impact on treatment: Final results from a prospective, multi-disciplinary study.
2016
·
Sachdev P. Thomas
, Fadi S. Braiteh
, et al.
·
Journal of Clinical Oncology
·
1
Author response: Lipid-mediated regulation of SKN-1/Nrf in response to germ cell absence
2015
·
Michael J Steinbaugh
, Sri Devi Narasimhan
, et al.
·
eLife
·
1
Predictive testing for selection of patients for extended endocrine therapy: Clinical utilization of Breast Cancer Index (BCI) in early-stage, ER+, LN- breast cancer.
2015
·
Stephen C. Malamud
, Brock Schroeder
, et al.
·
Journal of Clinical Oncology
·
1
Gene expression profiling: a validated molecular complement to standard clinicopathologic evaluation in difficult-to-diagnose metastatic tumors.
2012
·
Theresa N Operaña
, Brock E Schroeder
·
PubMed
·
1
Molecular classification of difficult to diagnose metastatic cancers and characterization of young patients: Clinical experience with the 92-gene assay in >22,000 cases.
2016
·
F Anthony Greco
, David R. Spigel
, et al.
·
Journal of Clinical Oncology
Abstract P5-08-09: Differential patient stratification by the breast cancer index HoxB13/IL17BR ratio vs recurrence score (RS) plus quantitative ER expression in hormone receptor positive, node negative breast cancer
2016
·
MJ Naughton
, BE Schroeder
, et al.
·
Cancer Research
Clinical utility and actionability of a combinatorial approach utilizing molecular diagnosis and biomarker profiling for cancers with unknown or differential diagnoses that were diagnosed as NSCLC.
2015
·
Nitin Kapoor
, Theresa N. Operana
, et al.
·
Journal of Clinical Oncology
Molecular profiling with the 92-gene assay and decision-impact on cancer treatment: Interim results from a prospective, multidisciplinary study.
2015
·
Sachdev P. Thomas
, Fadi S. Braiteh
, et al.
·
Journal of Clinical Oncology
Complementary approaches using cancer classification and mutational profiling for molecular characterization of clinically challenging tumors.
2014
·
Brock Schroeder
, Theresa N. Operana
, et al.
·
Journal of Clinical Oncology
Use of the 92-gene assay to identify tumor type and direct predictive biomarker testing in limited tissue specimens.
2013
·
Theresa N. Operana
, Brock Schroeder
, et al.
·
Journal of Clinical Oncology
A tale of two drug metabolizing enzymes : the CYP1A1-GFP transgenic mouse and the promiscuous nature of UGTs
2008
·
Theresa N. Operaña
·
eScholarship (California Digital Library)
Oligomerization of UDP‐Glucuronosyltransferases Visualized by Fluorescence Resonance Energy Transfer (FRET) in Living Cells.
2007
·
Theresa N. Operana
, Robert H. Tukey
·
The FASEB Journal
CYP1A1 regulation by oral exposure to benzo[a]pyrene using a CYP1A1 GFP transgenic mouse model
2006
·
Theresa N. Operana
, Nghia Nguyen
, et al.
·
The FASEB Journal
Show more works
View as search
Works count:
21
Citation count:
380
H-index:
6
I10-index:
4
Year
Topic
Type